LUPIN - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 4.1
| Stock Code | LUPIN | Market Cap | 1,07,088 Cr. | Current Price | 2,344 ₹ | High / Low | 2,381 ₹ |
| Stock P/E | 19.4 | Book Value | 596 ₹ | Dividend Yield | 0.51 % | ROCE | 21.9 % |
| ROE | 17.8 % | Face Value | 2.00 ₹ | DMA 50 | 2,289 ₹ | DMA 200 | 2,150 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | -0.26 % | PAT Qtr | 1,241 Cr. | PAT Prev Qtr | 869 Cr. |
| RSI | 56.0 | MACD | 8.45 | Volume | 15,09,484 | Avg Vol 1Wk | 11,84,902 |
| Low price | 1,837 ₹ | High price | 2,381 ₹ | PEG Ratio | 0.11 | Debt to equity | 0.04 |
| 52w Index | 93.3 % | Qtr Profit Var | 18.6 % | EPS | 120 ₹ | Industry PE | 30.9 |
📊 Analysis: Lupin (LUPIN) is a fundamentally strong pharma company with attractive valuations. Current P/E (19.4) is below industry average (30.9), making it undervalued relative to peers. ROE (17.8%) and ROCE (21.9%) are healthy, reflecting efficient capital usage. PEG ratio (0.11) indicates excellent growth potential. Dividend yield (0.51%) provides modest income. Debt-to-equity (0.04) is very low, showing financial strength. Technicals (RSI 56.0, MACD positive, price near 52-week high) suggest consolidation. Quarterly PAT growth (1,241 Cr. vs 869 Cr.) is strong, supporting long-term prospects.
💰 Entry Price Zone: Ideal entry would be in the 2,150–2,250 ₹ range, aligning with DMA 200 and 50 support levels. Current price (2,344 ₹) is slightly above comfort zone, making fresh entry acceptable but better on dips.
📈 Exit / Holding Strategy: Existing holders should maintain a long-term horizon (5+ years) given strong fundamentals and growth potential. Partial profit booking can be considered near 2,350–2,380 ₹ (recent highs). Long-term investors should continue holding, as Lupin offers both growth and dividend income, with potential re-rating closer to industry P/E levels.
Positive
- ✅ Strong market capitalization (1,07,088 Cr.) ensures stability
- ✅ Healthy ROE (17.8%) and ROCE (21.9%)
- ✅ Very low debt-to-equity (0.04)
- ✅ Strong quarterly PAT growth (+18.6%)
Limitation
- ⚠️ Stock trading near 52-week high, limiting immediate upside
- ⚠️ DII holdings slightly reduced (-0.26%)
- ⚠️ EPS (120 ₹) strong, but valuation re-rating may take time
Company Negative News
- 📉 DII holdings reduced (-0.26%)
- 📉 Stock price close to resistance zone (2,381 ₹)
Company Positive News
- 📈 PAT growth from 869 Cr. to 1,241 Cr.
- 📈 FII holdings increased (+0.20%), showing foreign confidence
Industry
- 🏭 Pharma sector has strong long-term demand drivers
- 🏭 Industry P/E (30.9) higher than Lupin’s, highlighting undervaluation
Conclusion
🔎 Lupin is a fundamentally strong, undervalued pharma leader with excellent efficiency metrics and growth potential. New investors can enter around 2,150–2,250 ₹ for long-term gains. Existing holders should maintain a 5+ year horizon, booking partial profits near highs (2,350–2,380 ₹). Lupin offers both growth and dividend income, making it a solid candidate for long-term investment.